A phase I, three part study, in healthy subjects to assess the safety, tolerability and pharmacokinetics of single and multiple doses of DSP-2230, and the effect of the administration in the fed and fasted states on the pharmacokinetics of DSP-2230

Trial Profile

A phase I, three part study, in healthy subjects to assess the safety, tolerability and pharmacokinetics of single and multiple doses of DSP-2230, and the effect of the administration in the fed and fasted states on the pharmacokinetics of DSP-2230

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2016

At a glance

  • Drugs DSP 2230 (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 28 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top